<DOC>
	<DOCNO>NCT02746159</DOCNO>
	<brief_summary>The purpose Registry enroll patient present clinical hemodynamic abnormality native synthetic ( graft ) arteriovenous ( AV ) fistula locate arm . Subjects treat Lutonix DCB carry CE Mark per current IFU follow clinically minimum 12 month .</brief_summary>
	<brief_title>Lutonix® Global AV Registry</brief_title>
	<detailed_description />
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Arteriovenous Fistula</mesh_term>
	<criteria>1 . Male nonpregnant , nonbreastfeeding female ≥18 year age ; 2 . Patient willing provide inform consent , willing comply protocolrequired follow visit ; 3 . Native synthetic ( graft ) arteriovenous fistula locate arm , include central vein , present clinical , physiological hemodynamic abnormality warrant angiographic imaging define K/DOQI guideline ; 4 . Lesion ( ) treat available Lutonix DCB device size matrix per current IFU . Patients exclude ANY follow condition apply : 1 . Patient currently participate investigational drug device study yet reach primary endpoint previously enrol registry ( i.e . Lutonix Global AV registry ) . 2 . Patient noncontrollable allergy contrast ; 3 . Patient another medical condition , opinion Investigator , may confound data interpretation associate life expectancy insufficient allow completion patient registry procedure follow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>